Clinical trial

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine…

NCT00449878 · Anthera Pharmaceuticals, Industry · Completed

Key facts

NCT number NCT00449878
Title Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Official title A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Acronym DIGEST
Lead sponsor Anthera Pharmaceuticals, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Intervention type Drug
Interventions Liprotamase, Placebo
Enrollment 163
Start date May 1, 2007
Primary completion Jun 1, 2008
Completion Jun 1, 2008
First posted Mar 21, 2007
Last update posted Oct 24, 2014
Countries United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies